Encompass Health Co. (NYSE:EHC - Get Free Report) CAO Andrew L. Price sold 5,042 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Encompass Health Trading Up 2.1 %
Shares of Encompass Health stock opened at $100.10 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. The stock's 50 day simple moving average is $96.00 and its 200-day simple moving average is $95.46. The stock has a market cap of $10.08 billion, a P/E ratio of 22.44, a P/E/G ratio of 1.18 and a beta of 0.90. Encompass Health Co. has a 1-year low of $72.57 and a 1-year high of $104.55.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.12. Encompass Health had a return on equity of 18.06% and a net margin of 8.48%. Analysts predict that Encompass Health Co. will post 4.76 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently weighed in on EHC shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $110.00 target price on shares of Encompass Health in a research note on Tuesday. William Blair reiterated an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. Barclays upped their price target on shares of Encompass Health from $116.00 to $118.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. KeyCorp lifted their price objective on Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a report on Monday. Finally, Truist Financial reissued a "buy" rating and set a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $107.67.
Get Our Latest Report on EHC
Institutional Investors Weigh In On Encompass Health
A number of hedge funds have recently modified their holdings of the company. Norges Bank purchased a new position in Encompass Health during the fourth quarter worth about $100,637,000. Raymond James Financial Inc. acquired a new stake in shares of Encompass Health during the 4th quarter worth approximately $77,944,000. Point72 Asset Management L.P. raised its position in shares of Encompass Health by 2,458.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company's stock valued at $83,990,000 after buying an additional 835,135 shares during the period. Jennison Associates LLC acquired a new position in Encompass Health in the fourth quarter valued at approximately $52,094,000. Finally, abrdn plc purchased a new position in Encompass Health in the fourth quarter worth approximately $17,846,000. Hedge funds and other institutional investors own 97.25% of the company's stock.
About Encompass Health
(
Get Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
